NCT04556162 is a clinical trial of fractional sodium excretion in Salt; Deficit (or Low), sponsored by University Hospital, Ghent.

Who is sponsoring NCT04556162?

NCT04556162 is sponsored by University Hospital, Ghent.

What drugs are being tested in NCT04556162?

Interventions in NCT04556162: fractional sodium excretion, risk subgroups.

What condition does NCT04556162 study?

NCT04556162 studies Salt; Deficit (or Low), Cystic Fibrosis.

Is NCT04556162 still recruiting?

NCT04556162 is currently completed. Last updated 1 December 2022.

Last reviewed 2022-12-01 · How we verify

NCT04556162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Salt Status in Patients With Cystic Fibrosis

Completed Last updated 1 December 2022

What this trial tests

trial testing fractional sodium excretion in Salt; Deficit (or Low) in 222 participants. Completed in 21 November 2021.

Timeline

1 January 2018

Primary endpoint
21 November 2021

21 November 2021

Quick facts

Lead sponsor	University Hospital, Ghent
Status	Completed
Study type	OBSERVATIONAL
Enrollment	222
Start date	1 January 2018
Primary completion	21 November 2021
Estimated completion	21 November 2021
Sites	1 location across Belgium

Drugs / interventions tested

fractional sodium excretion
risk subgroups

Conditions studied

Salt; Deficit (or Low) — all drugs for Salt; Deficit (or Low) →
Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

University Hospital, Ghent

Who can join

Eligibility, any sex, with Salt; Deficit (or Low) or Cystic Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The results of the annual check-up will be collected to evaluate the best urinary marker for fractional sodium excretion and salt status will be correlated to clinical outcome measures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Ghent trials

Trials by the same sponsor.

NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04556162 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
Last refreshed: 1 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04556162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing